Startup Fortis has emerged from stealth mode with an $18 million Series A financing led by Avalon Ventures.
BMS has partnered with Nektar Therapeutics in a clinical collaboration that aims to boost the efficacy of Opdivo with Nektar candidate NKTR-214.
With its measurable impact on patient survival, there’s no denying that immunotherapy is already causing momentum in ways that cancer is treated. Learn more…
Amgen’s Kyprolis has come up short against Takeda’s Velcade in a Phase III trial in patients newly diagnosed with multiple myeloma.
Kite Pharma has posted an interim analysis of Phase II CAR-T data it thinks are strong enough to support regulatory approval.
Array BioPharma was up about 57% in early trading on top-line Phase III data for its combo of two investigational skin cancer candidates.
GW Pharma has clocked a third set of positive pivotal trial data, which makes it an even more attractive potential purchase.
British biotech Adaptimmune Therapeutics has partnered with MD Anderson Cancer Center to develop novel adoptive T-cell therapies for use across several types…
Sino-American biotech MicuRx Pharmaceuticals has raised $55 million to fund a pair of late-phase trials of its antibiotic.
Regeneron and Sanofi have snagged a priority review for their potential blockbuster atopic dermatitis drug, dupilumab.
Mologen is seeking to raise €16 million to fund a suite of trials of its TLR9 agonist in patients with colorectal cancer, small cell lung cancer and HIV.